doi:10.1016/j.bmcl.2004.09.015
Copyright © 2004 Elsevier Ltd All rights reserved.
Biological evaluation of novel estrogen-platinum(II) hybrid molecules on uterine and ovarian cancers—molecular modeling studies
References and further reading may be available for this article. To view references and further reading you must
purchase this article.
Véronique Gagnona, Marie-Ève St-Germaina, Caroline Descôteauxa, Josée Provencher-Mandevillea, Sophie Parenta, Sanat K. Mandalb, Eric Asselina and Gervais Bérubéa,
, 
aDépartement de Chimie-Biologie, GRBCM, Université du Québec à Trois-Rivières, C.P. 500, Trois-Rivières, Québec, Canada G9A 5H7
bDivision of Science & Technology, College of the North Atlantic, Clarenville Campus, Clarenville, Newfoundland, Canada A5A 1V9
Received 12 July 2004;
revised 4 September 2004;
accepted 7 September 2004.
Available online 28 September 2004.
Graphical abstract
The biological activity of hybrids 2 was evaluated in vitro on human uterine and ovarian cancers. The molecules present high affinity for the estrogen receptor alpha. The cytotoxicity and the affinity of 2 are explained by molecular modeling analysis.
Abstract
We have recently reported the synthesis of a series of original 17β-estradiol-linked platinum(II) hybrid molecules. The biological activity of these compounds was evaluated in vitro on estrogen dependent and independent (ER+ and ER−) human uterine and ovarian cancers. The hybrid molecules present higher affinity than that of 17β-estradiol for the estrogen receptor alpha (ERα). The cytotoxicity and the affinity of the hybrid molecules are explained using molecular modeling analysis. This study further confirms that the derivatives made of a 2-(2′-aminoethyl)pyridine ligand displayed superior activity against the cell lines particularly when the connecting arm is 8–10 carbon atoms long. Molecular modeling shows that a long side chain can facilitate the access of the platinum(II) moiety to DNA. The novel compounds also prove to be moderately cytotoxic against platinum resistant endometrial and ovarian cancer cell lines.
Keywords: Estrogen-platinum(II) hybrids; Cytotoxic agents; Endometrial and ovarian cancers; Estrogen receptor; Molecular modeling
Scheme 1. Structure of the platinum(II) complexes studied.
Figure 1. Estrogen receptor binding affinity (ERα) ED-estradiol: enzyme donor-estradiol; E2: 17β-estradiol. Cisplatin, 1 (m = 1 or 2) present no affinity for the ER.
Figure 2. 17β-Estradiol within the active site of the ER (PDB, 1ERE). The main interactions are occurring on ring A of the steroid nucleus, there are three hydrogen bonds (HB).
Figure 3. CD-50 in the active site showing additional HB, blue labels, when compared to CD-38 (Fig. 4) or 17β-estradiol (Fig. 2). CD-50 presents seven HB.
Figure 4. CD-38 in the active site of the ER. There are four HB.
Figure 5. Surroundings of the platinum atom of CD-50 (left) and CD-38 (right) within the ER. The chlorine atoms (green) in CD-50 and CD-38 are pointing very differently. The platinum atom is more hindered for CD-50 than for CD-38 (yellow label) and thus unavailable for binding to DNA.
Table 1.
Inhibitory concentrationa of cisplatin, 1 and 2 (m = 1) on both ER+ and ER− uterine and ovarian cancer cell lines
a Inhibitory concentration (IC
50, μM) as obtained by the MTT assay. Experiments were performed in duplicates and the results represent the mean ± SEM of three independent experiments. NR (not reached) = IC
50 > 40 μM.
Table 2.
Inhibitory concentrationa of cisplatin, 1 and 2 (m = 2) on both ER+ and ER− uterine and ovarian cancer cell lines
a Inhibitory concentration (IC
50, μM) as obtained by the MTT assay. Experiments were performed in duplicates and the results represent the mean ± SEM of three independent experiments. NR (not reached) = IC
50 > 40 μM.
Table 3.
Affinity for the estrogen receptor α (ERα)

ND = not determined, NA = not available.

Corresponding author. Tel.: +1 81 9376 5011 3353; fax: +1 81 9376 5084